Biopharma patents in China: Litigation, licensing, and patent linkage
Published on: March 15, 2022 16:42
As the past two years have shown, the biopharmaceutical industry is more important than ever in producing drugs that improve and save lives. For U.S. biopharmaceutical companies, China continues to be an important market. Securing and enforcing intellectual property (IP) rights in China is critical for U.S. companies to succeed in this growing market and to recoup the tremendous investments in development of new medicines.
Other ways to view this video